Lakefront Biotherapeutics GLPGF Stock
Lakefront Biotherapeutics Price Chart
Lakefront Biotherapeutics GLPGF Financial and Trading Overview
| Lakefront Biotherapeutics stock price | 48.7 USD |
| Previous Close | 34 USD |
| Open | 26.2 USD |
| Bid | 31.38 USD x 10000 |
| Ask | 33.42 USD x 10000 |
| Day's Range | 26.2 - 26.2 USD |
| 52 Week Range | 26.2 - 34 USD |
| Volume | 190 USD |
| Avg. Volume | 1 USD |
| Market Cap | 3.19B USD |
| Beta (5Y Monthly) | 0.112 |
| PE Ratio (TTM) | 4.629277 |
| EPS (TTM) | 10.53 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GLPGF Valuation Measures
| Enterprise Value | -510395424 USD |
| Trailing P/E | 4.629277 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.21945 |
| Price/Book (mrq) | 0.83919543 |
| Enterprise Value/Revenue | -0.515 |
| Enterprise Value/EBITDA | -0.897 |
Trading Information
Lakefront Biotherapeutics Stock Price History
| Beta (5Y Monthly) | 0.112 |
| 52-Week Change | -21.55% |
| S&P500 52-Week Change | 19.66% |
| 52 Week High | 34 USD |
| 52 Week Low | 26.2 USD |
| 50-Day Moving Average | 27.49 USD |
| 200-Day Moving Average | 30.5 USD |
GLPGF Share Statistics
| Avg. Volume (3 month) | 1 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 65.48M |
| Float | 23.72M |
| Short Ratio | N/A |
| % Held by Insiders | 25.35% |
| % Held by Institutions | 43.25% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 60.23% |
| Operating Margin (ttm) | -359.29% |
| Gross Margin | 67.61% |
| EBITDA Margin | 57.43% |
Management Effectiveness
| Return on Assets (ttm) | 9.92% |
| Return on Equity (ttm) | 20.12% |
Income Statement
| Revenue (ttm) | 990.57M USD |
| Revenue Per Share (ttm) | 15.03 USD |
| Quarterly Revenue Growth (yoy) | -81.50% |
| Gross Profit (ttm) | 669.75M USD |
| EBITDA | 568.92M USD |
| Net Income Avi to Common (ttm) | 594.32M USD |
| Diluted EPS (ttm) | 10.52 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.24B USD |
| Total Cash Per Share (mrq) | 34.11 USD |
| Total Debt (mrq) | 6.36M USD |
| Total Debt/Equity (mrq) | 0.2 USD |
| Current Ratio (mrq) | 32.839 |
| Book Value Per Share (mrq) | 58.031776 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -226908992 USD |
| Levered Free Cash Flow (ttm) | 138.21M USD |
Profile of Lakefront Biotherapeutics
| Country | United States |
| State | N/A |
| City | Mechelen |
| Address | SchaliEnhoevedreef 20 T |
| ZIP | 2800 |
| Phone | 32 1 534 29 00 |
| Website | https://lakefrontbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 196 |
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Q&A For Lakefront Biotherapeutics Stock
What is a current GLPGF stock price?
Lakefront Biotherapeutics GLPGF stock price today per share is 48.7 USD.
How to purchase Lakefront Biotherapeutics stock?
You can buy GLPGF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lakefront Biotherapeutics?
The stock symbol or ticker of Lakefront Biotherapeutics is GLPGF.
Which industry does the Lakefront Biotherapeutics company belong to?
The Lakefront Biotherapeutics industry is Biotechnology.
How many shares does Lakefront Biotherapeutics have in circulation?
The max supply of Lakefront Biotherapeutics shares is 65.48M.
What is Lakefront Biotherapeutics Price to Earnings Ratio (PE Ratio)?
Lakefront Biotherapeutics PE Ratio is 4.62488130 now.
What was Lakefront Biotherapeutics earnings per share over the trailing 12 months (TTM)?
Lakefront Biotherapeutics EPS is 10.53 USD over the trailing 12 months.
Which sector does the Lakefront Biotherapeutics company belong to?
The Lakefront Biotherapeutics sector is Healthcare.
